INDIRECT COMPARISON OF PEMBROLIZUMAB TO VEMURAFENIB AND DABRAFENIB MONOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BRAF MUTATION POSITIVE IPILIMUMAB NAIVE PATIENTS

被引：1
|
作者：
Jansen, J. P. [1 ]
Stevinson, K. [2 ]
Wang, J. [3 ]
机构：
[1] Precis Hlth Econ, San Francisco, CA USA
[2] Merck & Co Inc, Lebanon, NJ USA
[3] Merck & Co Inc, North Wales, PA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1650
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN28
引用
收藏
页码：A138 / A138
页数：1
相关论文
共 50 条
  • [41] First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
    Long, Georgina V.
    Lipson, Evan J.
    Hodi, F. Stephen
    Ascierto, Paolo A.
    Larkin, James
    Lao, Christopher
    Grob, Jean-Jacques
    Ejzykowicz, Flavia
    Moshyk, Andriy
    Garcia-Horton, Viviana
    Zhou, Zheng-Yi
    Xin, Yiqiao
    Palaia, Jennell
    Mcdonald, Laura
    Keidel, Sarah
    Salvatore, Anthony
    Patel, Divya
    Sakkal, Leon A.
    Tawbi, Hussein
    Schadendorf, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (33)
  • [42] A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
    Tarhini, A. A.
    Toor, K.
    Chan, K.
    McDermott, D. F.
    Mohr, P.
    Larkin, J.
    Hodi, F. S.
    Lee, C-H
    Rizzo, J., I
    Johnson, H.
    Moshyk, A.
    Rao, S.
    Kotapati, S.
    Atkins, M. B.
    ESMO OPEN, 2021, 6 (02)
  • [43] A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancer
    Nogami, Naoyuki
    Umemura, Shigeki
    Kozuki, Toshiyuki
    Zenke, Yoshitaka
    Ohtani, Junko
    Ishii, Mikio
    Han, Shirong
    Noguchi, Kazuo
    Horinouchi, Hidehito
    RESPIRATORY INVESTIGATION, 2025, 63 (03) : 296 - 302
  • [44] An Indirect Treatment Comparison of Lenvatinib for the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma
    Ndirangu, Kerigo
    Paine, Abby
    Pilkington, Hollie
    Trueman, David
    ADVANCES IN THERAPY, 2025, 42 (02) : 977 - 994
  • [45] First-line atezolizumab monotherapy in patients with advanced BRAFV600 wild-type melanoma
    de Azevedo, Sergio Jobim
    de Melo, Andreia Cristina
    Roberts, Louise
    Caro, Ivor
    Xue, Cloris
    Wainstein, Alberto
    PIGMENT CELL & MELANOMA RESEARCH, 2021, 34 (05) : 973 - 977
  • [46] Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy
    Noordhof, A. L.
    Damhuis, R. A. M.
    Hendriks, L. E. L.
    de Langen, A. J.
    Timens, W.
    Venmans, B. J. W.
    van Geffen, W. H.
    LUNG CANCER, 2021, 155 : 163 - 169
  • [47] Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
    Long, G. V.
    Arance, A.
    Mortier, L.
    Lorigan, P.
    Blank, C.
    Mohr, P.
    Schachter, J.
    Grob, J. -J.
    Lotem, M.
    Middleton, M. R.
    Neyns, B.
    Steven, N.
    Ribas, A.
    Walpole, E.
    Carlino, M. S.
    Lebbe, C.
    Sznol, M.
    Jensen, E.
    Leiby, M. A.
    Ibrahim, N.
    Robert, C.
    ANNALS OF ONCOLOGY, 2022, 33 (02) : 204 - 215
  • [48] Cost-effectiveness of new therapies in first-line treatment of advanced melanoma for patients with independent BRAF mutation status from a Brazilian private payer perspective.
    Matteucci, Christina
    Lima, Joao P. S. D. N.
    Bernardino, Graziela
    Oliveira, Ana Paula
    Maia, Daniela Galdeano
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF DABRAFENIB PLUS TRAMETINIB VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAIVE METASTATIC BRAF V600 MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Tai, T. A.
    Perampaladas, K.
    Cooney, P.
    Mensah, L.
    Jameson, K.
    Rafia, R.
    Bains, R.
    Kane, N.
    VALUE IN HEALTH, 2023, 26 (12) : S49 - S49
  • [50] Systematic review and indirect treatment comparison (ITC) of dabrafenib (Dab) and trametinib (Tram) versus first-line (1L) treatments for metastatic melanoma (MM).
    Srivastava, Kunal
    Pathak, Purnima
    Amonkar, Mayur
    Stapelkamp, Ceilidh
    Swann, R. Suzanne
    Casey, Michelle
    Rana, Cheena
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345